FDA Opts For MedGuide, Not Black Box For Anti-Epileptic Suicidality
Executive Summary
FDA has made a decision on how to communicate the suicidality risk for anti-epileptic drugs: with the first novel approvals in that class since an advisory committee on the topic, FDA has opted for a Medication Guide over a "black box" warning
You may also be interested in...
Lundbeck Onfi Gets Dermatological Warning, Bigger Marketing Challenge
Labeling for Eisai’s Banzel, which also has an indication limited to Lennox-Gastaut syndrome, does not mention Stevens-Johnson syndrome or toxic epidermal necrolysis cited in the Onfi warning.
Equetro Web Pages Omit Risk Info, Make Unsupported Claims On Depression, FDA Says
The agency sent Validus Pharmaceuticals a letter objecting to web pages that minimize the risk of suicidality with use of the bipolar disorder drug and suggest it does not worsen depression or induce weight gain.
Historical Controls For Epilepsy Studies To Be Considered By Advisory Cmte.
GlaxoSmithKline's Lamictal XR and several drugs in the pipeline could see their quest for monotherapy indications affected by what the Peripheral and Central Nervous System Drugs Advisory Committee decides.